MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

DownloadDownload image
Issuance of common stockunder inducement...$6,473K Issuance of commonwarrants under february...$4,531K Issuance of common stockunder open market...$1,305K Issuance of common stockunder february 2025...$996K Proceeds from sale ofproperty and equipment$110K Pre-funded warrantsexercise$2K Net cash provided byfinancing activities$13,189K Net cash provided byinvesting activities$108K Canceled cashflow$118K Canceled cashflow$2K Increase (decrease) incash and cash...-$13,093K Canceled cashflow$13,297K Ipr&d impairment$11,842K Depreciation$2,922K Other current assets-$2,243K Stock-based compensation$2,091K Other long-livedasset impairment$1,653K Trade accountpayables$1,238K Finance expense(income), net-$256K Loss from sale anddisposal of fixed assets,...-$205K February 2025 spaissuance costs$118K Purchase of property andequipment$2K Net cash used inoperating activities-$26,390K Canceled cashflow$22,450K Net loss-$36,199K Income from change infair value of...$6,111K Other accountpayables-$3,430K Gain from early leasetermination$2,949K Revaluation of contingentconsideration-$77K Net change inoperating leases-$74K
Cash Flow
source: myfinsight.com

BiomX Inc. (PHGE)

BiomX Inc. (PHGE)